Craig Sauter, MD
Hematology · Cleveland, OHNPI 1447494612
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,058 of the $51,027 with a category attached, or 70.7%. 18 manufacturers reported payments, led by Gilead at 37.5% of the total. Reporting peaked in 2019 at $22,562 and has fallen 98.7% since, to $292 in 2025.
Across 59 payments — averaging $864.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$19K
- Bristol Myers Squibb$8K
- GSK$6K
- Novartis$5K
- Ipsen Biopharmaceuticals, Inc$4K
- Morphosys, US Inc.$3K
- plus $6K from 12 others
Across 29 payments — averaging $94,334 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2M
- Sanofi$459K
- Bristol Myers Squibb$203K
- Gilead$40K
What the payments were for
- Consulting fees$36,05871%
- Speaking & faculty fees$10,21820%
- Travel & lodging$2,3005%
- Food & beverage$2,4315%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 19 | $19,158 |
| Bristol Myers Squibb | 8 | $8,057 |
| GSK | 1 | $6,376 |
| Novartis | 5 | $4,739 |
| Ipsen Biopharmaceuticals, Inc | 1 | $4,350 |
| Morphosys, US Inc. | 1 | $2,768 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,140 |
| Karyopharm Therapeutics Inc. | 1 | $1,938 |
| ADC Therapeutics America, Inc. | 5 | $375 |
| Genmab U.S., Inc. | 5 | $353 |
| Biolinerx USA, Inc. | 3 | $264 |
| Seagen Inc. | 1 | $172 |
| National Marrow Donor Program | 1 | $156 |
| Rigel Pharmaceuticals, Inc. | 1 | $53 |
| AbbVie | 1 | $46 |
| Stemline Therapeutics Inc. | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Medline Industries LP | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,027 in reported general payments places this provider in the 80th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 34 | $677,960 |
| CresembaIsavuconazonium Sulfate | 12 | $73,524 |
| Posaconazole | 13 | $23,067 |
| Sirolimus | 11 | $12,556 |
| Atovaquone | 12 | $5,793 |
| Acyclovir | 100 | $1,379 |
| ValacyclovirValacyclovir Hcl | 11 | $641 |
| Pantoprazole Sodium | 25 | $167 |
| Prednisone | 35 | $106 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 37 | $100 |
| Amoxicillin | 20 | $84 |
| Amlodipine Besylate | 18 | $30 |
Paid to pharmacies, not to this prescriber.
Other hematology in Cleveland
- Jaroslaw MaciejewskiCleveland$233K
- Leland MethenyCleveland$124K
- Anjali AdvaniCleveland$79K
- John MolinaCleveland$39K
- Hooman RashidiCleveland$2K
- Uma BorateColumbus$323K
- Sam PenzaColumbus$256K
- Spero CatalandColumbus$245K
- Kami MaddocksColumbus$236K
- Narendranath EpperlaColumbus$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.